Aller au contenu principal
Fermer

MEDTECH : EIGHT NEW ROSA ROBOTS SOLD IN FISCAL Q2 2016 / SALES INCLUDE THE FIRST ON THE AUSTRALIAN MARKET
information fournie par Actusnews 05/01/2016 à 18:30

Montpellier, France, January 5th, 2016 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, announced eight new sales of its ROSA™ robot during its fiscal second quarter 2016 (October 1 to December 31, 2015).

These sales were made in the United States of America, the United Kingdom and, for the first time, in Australia. The sales show significant growth for Medtech, as three ROSA™ robots were sold during the same period the previous year.

Bertin Nahum, CEO and Founder of Medtech, said: “We are delighted with the results for this quarter as they confirm the strong acceleration in sales and demonstrate the high performance of our ROSA™ robot's commercial deployment on the American, European and now Australian markets.”

Sales made over the last quarter in detail follow:

Australia :

This first sale in Australia was made to Mater Hospital (Brisbane) through Medtech's distributor, Surgicom, about six months after receiving approval for sale on the Australian market and signing the distribution contract.

United Kingdom:

Harley Street Clinic (London) is an internationally-famous private establishment renowned for oncology, cardiology and neuroscience. The pediatric neurosurgery department is the largest private unit of its kind in the country.

United States:

New York-Presbyterian Hospital / Columbia University Medical Center (New York) specializes in the treatment of epilepsy. After acquiring its first robot in February 2015, this American center made a second ROSA™ robot acquisition.

St. Louis Children's Hospital, Washington University (Saint Louis) is one of the most prestigious hospital establishments specialized in pediatric medical and surgical care. In 2015, it was classified among the best American hospitals for children by U.S. News & World Report .

Children's Hospital of Atlanta (Georgia) is the largest American pediatric establishment, according to the 2013 figures from the public health information system. The hospital was also classified among the best 10 American pediatric hospitals in terms of quality of care by U.S. News & World Report.

Children's Hospital Colorado (Aurora, Colorado) is a prestigious private pediatric establishment, famous for its treatment of epilepsy. This hospital center was also recognized by U.S. News & World Report for its quality of care.

Norton Browsboro Hospital (Louisville, Kentucky) is a renowned hospital for the treatment of neurological disorders such as epilepsy.

Harborview Medical Center (Seattle, Washington) offers high quality health care in the field of neurosurgery, and specializes in the treatment of severe epilepsy.

Next communication: Figures for the 2015/2016 half-yearly report (ended 31/12/2015) to be published on January 12, 2016, before the stock exchange.


About MEDTECH

Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
CONTACT MEDTECH
Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40
INVESTORS
Corinne Puissant
Tel : +33 (0)1 53 67 36 77
cpuissant@actus.fr
PRESS
Alexandra Prisa (EU) Joanna Zimmerman (US)
Tel. : +33(0)1 53 67 36 90 Tel : +1 646-536-7006
aprisa@actus.fr jzimmerman@theruthgroup.com

Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-42624-201601-MEDTECH-CP-T2-2015-VDEF_ENG.pdf

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

  • billet yens (Crédits: Adobe Stock)
    information fournie par Reuters 19.12.2025 08:10 

    par Jamie McGeever Le yen japonais JPY= a été la devise la moins performante par rapport au dollar américain meurtri en 2025, même si la Banque du Japon a été la seule grande banque centrale à relever ses taux d'intérêt . La poursuite du resserrement ne garantira ... Lire la suite

  • Le siège d'Emeis. (Crédit:  / Emeis)
    information fournie par AOF 19.12.2025 08:06 

    (AOF) - emeis annonce avoir finalisé avec ses partenaires bancaires et des investisseurs financiers la levée de nouveaux financements pour un total de 3,15 milliards d'euros, avec une maturité moyenne de 5,5 années et une marge moyenne sur l’Euribor de 247 points ... Lire la suite

  • Bâtiment de la Banque centrale française à Paris
    information fournie par Reuters 19.12.2025 08:02 

    La Banque de France (BdF) a relevé vendredi sa prévision de croissance économique pour 2025, ‍à la faveur d'un "pic d'activité" inattendu au troisième trimestre. L'institut table désormais sur une progression de 0,9% du produit intérieur brut (PIB) cette année, ... Lire la suite

  • Logo d'Ipsen à Boulogne-Billancourt
    information fournie par Reuters 19.12.2025 08:00 

    Ipsen a annoncé vendredi ‍que l'essai pivotal de Phase II FALKON pour ‌son médicament expérimental, le fidrisertib contre la ​fibrodysplasie ossifiante progressive (FOP), ⁠n'a pas atteint son critère principal, engendrant ⁠la ‍clôture de l'étude. Le médicament ... Lire la suite

Mes listes

Cette liste ne contient aucune valeur.
Chargement...